Antitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models

DZ Qian, YF Wei, X Wang, Y Kato, L Cheng… - The Prostate, 2007 - Wiley Online Library
BACKGROUND Histone deacetylase (HDAC) inhibitors represent a novel class of
therapeutic agents with antitumor activity currently in clinical development. In this study, we …
被引用次数：83 相关文章

[引用][C] Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

DZ QIAN, YF WEI, X WANG, Y KATO, L CHENG… - The …, 2007 - pascal-francis.inist.fr
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

DZ Qian, YF Wei, X Wang, Y Kato, L Cheng, R Pili - Prostate, 2007 - pure.johnshopkins.edu
BACKGROUND. Histone deacetylase (HDAC) inhibitors represent a novel class of
therapeutic agents with antitumor activity currently in clinical development. In this study, we …

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

DZ Qian, YF Wei, X Wang, Y Kato, L Cheng, R Pili - Prostate, 2007 - ohsu.elsevierpure.com
BACKGROUND. Histone deacetylase (HDAC) inhibitors represent a novel class of
therapeutic agents with antitumor activity currently in clinical development. In this study, we …

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

DZ Qian, YF Wei, X Wang, Y Kato, L Cheng, R Pili - The Prostate, 2007 - europepmc.org
Background Histone deacetylase (HDAC) inhibitors represent a novel class of therapeutic
agents with antitumor activity currently in clinical development. In this study, we tested the …

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

DZ Qian, YF Wei, X Wang, Y Kato, L Cheng… - The …, 2007 - pubmed.ncbi.nlm.nih.gov
Background Histone deacetylase (HDAC) inhibitors represent a novel class of therapeutic
agents with antitumor activity currently in clinical development. In this study, we tested the …

[引用][C] Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

DZ QIAN, YF WEI, W XIAOFEI, Y KATO, L CHENG… - The Prostate, 2007 - Wiley-Liss